PBS eases up on some cancer drug restrictions

A number of oncology-related PBS listings will change following requests from the Medical Oncology Group of Australia (MOGA). At its July 2018 meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended amending the current restriction level of pazopanib for renal cell carcinoma and soft tissue sarcoma from Authority Required to Authority Required (Streamlined). The amendment ...

Already a member?

Login to keep reading.

© 2021 the limbic